JP2016532457A5 - - Google Patents

Download PDF

Info

Publication number
JP2016532457A5
JP2016532457A5 JP2016547976A JP2016547976A JP2016532457A5 JP 2016532457 A5 JP2016532457 A5 JP 2016532457A5 JP 2016547976 A JP2016547976 A JP 2016547976A JP 2016547976 A JP2016547976 A JP 2016547976A JP 2016532457 A5 JP2016532457 A5 JP 2016532457A5
Authority
JP
Japan
Prior art keywords
cells
cell culture
cell
interest
metabolic shift
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016547976A
Other languages
English (en)
Japanese (ja)
Other versions
JP6663854B2 (ja
JP2016532457A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/059993 external-priority patent/WO2015054554A1/en
Publication of JP2016532457A publication Critical patent/JP2016532457A/ja
Publication of JP2016532457A5 publication Critical patent/JP2016532457A5/ja
Priority to JP2020024484A priority Critical patent/JP6967620B2/ja
Application granted granted Critical
Publication of JP6663854B2 publication Critical patent/JP6663854B2/ja
Priority to JP2021173755A priority patent/JP7377243B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016547976A 2013-10-11 2014-10-10 代謝が最適化された細胞培養 Active JP6663854B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2020024484A JP6967620B2 (ja) 2013-10-11 2020-02-17 代謝が最適化された細胞培養
JP2021173755A JP7377243B2 (ja) 2013-10-11 2021-10-25 代謝が最適化された細胞培養

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361889815P 2013-10-11 2013-10-11
US61/889,815 2013-10-11
PCT/US2014/059993 WO2015054554A1 (en) 2013-10-11 2014-10-10 Metabolically optimized cell culture

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020024484A Division JP6967620B2 (ja) 2013-10-11 2020-02-17 代謝が最適化された細胞培養

Publications (3)

Publication Number Publication Date
JP2016532457A JP2016532457A (ja) 2016-10-20
JP2016532457A5 true JP2016532457A5 (enExample) 2017-11-09
JP6663854B2 JP6663854B2 (ja) 2020-03-13

Family

ID=52813657

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016547976A Active JP6663854B2 (ja) 2013-10-11 2014-10-10 代謝が最適化された細胞培養
JP2020024484A Active JP6967620B2 (ja) 2013-10-11 2020-02-17 代謝が最適化された細胞培養
JP2021173755A Active JP7377243B2 (ja) 2013-10-11 2021-10-25 代謝が最適化された細胞培養

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020024484A Active JP6967620B2 (ja) 2013-10-11 2020-02-17 代謝が最適化された細胞培養
JP2021173755A Active JP7377243B2 (ja) 2013-10-11 2021-10-25 代謝が最適化された細胞培養

Country Status (17)

Country Link
US (2) US20160244725A1 (enExample)
EP (3) EP3351620B1 (enExample)
JP (3) JP6663854B2 (enExample)
KR (4) KR102358807B1 (enExample)
CN (2) CN114717196A (enExample)
AU (2) AU2014331776B2 (enExample)
CA (1) CA2926049C (enExample)
DK (2) DK3055409T3 (enExample)
EA (2) EA033783B1 (enExample)
ES (2) ES2833471T3 (enExample)
HU (2) HUE051049T2 (enExample)
IL (2) IL244511A0 (enExample)
MX (2) MX376623B (enExample)
PL (2) PL3055409T3 (enExample)
SG (2) SG10201800772TA (enExample)
WO (1) WO2015054554A1 (enExample)
ZA (1) ZA201601550B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2833471T3 (es) 2013-10-11 2021-06-15 Regeneron Pharma Cultivo celular metabólicamente optimizado
US11390663B2 (en) 2013-10-11 2022-07-19 Regeneron Pharmaceuticals, Inc. Metabolically optimized cell culture
US20160244726A1 (en) * 2013-10-11 2016-08-25 Regeneron Pharmaceuticals, Inc. Metabolically optimized cell culture
JP7260018B2 (ja) * 2017-03-31 2023-04-18 株式会社三洋物産 遊技機
JP7260011B2 (ja) * 2017-03-31 2023-04-18 株式会社三洋物産 遊技機
JP7260020B2 (ja) * 2017-03-31 2023-04-18 株式会社三洋物産 遊技機
JP7310947B2 (ja) * 2017-04-27 2023-07-19 株式会社三洋物産 遊技機
JP7272480B2 (ja) * 2017-04-27 2023-05-12 株式会社三洋物産 遊技機
JP7310952B2 (ja) * 2017-04-27 2023-07-19 株式会社三洋物産 遊技機
JP7260021B2 (ja) * 2017-04-27 2023-04-18 株式会社三洋物産 遊技機
JP7310945B2 (ja) * 2017-04-27 2023-07-19 株式会社三洋物産 遊技機
JP7260009B2 (ja) * 2017-04-27 2023-04-18 株式会社三洋物産 遊技機
JP7260012B2 (ja) * 2017-04-27 2023-04-18 株式会社三洋物産 遊技機
JP7260013B2 (ja) * 2017-04-27 2023-04-18 株式会社三洋物産 遊技機
JP7323512B2 (ja) 2017-10-06 2023-08-08 ロンザ リミテッド ラマン分光法を使用する細胞培養の自動制御
EP4039786A1 (en) 2017-10-16 2022-08-10 Regeneron Pharmaceuticals, Inc. Perfusion bioreactor and related methods of use
EP3717656B1 (en) * 2017-11-30 2024-03-13 F. Hoffmann-La Roche AG Process for culturing mammalian cells
MX2020010028A (es) * 2018-03-29 2020-10-14 Genentech Inc Actividad lactogenica modulada en celulas de mamifero.
GB201810772D0 (en) * 2018-06-29 2018-08-15 Ge Healthcare Bio Sciences Ab Method in bioprocess purification system
JP7231355B2 (ja) * 2018-08-22 2023-03-01 日機装株式会社 細胞培養方法および細胞培養装置
IL280880B2 (en) 2018-08-27 2025-04-01 Regeneron Pharma Using Raman Spectroscopy in Downstream Purification
JP2020151559A (ja) * 2020-06-24 2020-09-24 株式会社三洋物産 遊技機
JP2020151560A (ja) * 2020-06-24 2020-09-24 株式会社三洋物産 遊技機
EP3985097A1 (en) * 2020-10-14 2022-04-20 Sartorius Stedim Biotech GmbH A method and system for configuring and/or setup of a downstream process for processing a biomass

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
US6165741A (en) 1997-05-30 2000-12-26 The Trustees Of The University Of Pennsylvania Method for rapid detection of bacterial growth in cultures
US5972650A (en) 1997-06-26 1999-10-26 Brigham And Women's Hospital Tetracycline repressor regulated mammalian cell transcription and viral replication switch
US6919183B2 (en) 2001-01-16 2005-07-19 Regeneron Pharmaceuticals, Inc. Isolating cells expressing secreted proteins
US6953692B2 (en) * 2001-12-18 2005-10-11 Bayer Pharmaceuticals Corporation Device and method for seed-train expansion of mammalian cells
US7039770B1 (en) 2002-03-05 2006-05-02 Juniper Networks, Inc. Low latency request dispatcher
CA2417689C (en) 2002-03-05 2006-05-09 F. Hoffmann-La Roche Ag Improved methods for growing mammalian cells in vitro
US8673589B2 (en) 2002-05-29 2014-03-18 Regeneron Pharmaceuticals, Inc. Inducible eukaryotic expression system
SI1623019T1 (sl) 2003-05-15 2010-10-29 Wyeth Llc Omejeno glukozno dovajanje za živalsko celično kulturo
US7531327B2 (en) * 2004-07-23 2009-05-12 Immunomedics, Inc. Methods and compositions for increasing longevity and protein yield from a cell culture
TWI374935B (en) 2004-08-27 2012-10-21 Pfizer Ireland Pharmaceuticals Production of α-abeta
US7300773B2 (en) * 2004-08-27 2007-11-27 Wyeth Research Ireland Limited Production of TNFR-Ig
CA2628340A1 (en) * 2005-11-02 2007-05-18 Wyeth Methods for adapting mammalian cells
US10155816B2 (en) 2005-11-28 2018-12-18 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
US7575890B2 (en) 2006-01-18 2009-08-18 Oxygen Enterprises, Ltd. Method for rapid detection and evaluation of cultured cell growth
CA2666317C (en) 2006-11-03 2013-08-06 Wyeth Glycolysis-inhibiting substances in cell culture
WO2008151219A1 (en) 2007-06-04 2008-12-11 Regeneron Pharmaceuticals, Inc. Enhanced expression and stability regions
EP3327132A3 (en) 2007-08-09 2018-07-18 Wyeth LLC Use of perfusion to enhance production of fed-batch cell culture in bioreactors
SI2331678T1 (sl) * 2008-06-13 2015-12-31 Janssen Biotech, Inc. Postopki za dobivanje visoke gostote viabilnih celic v sesalski celični kulturi
US8470552B2 (en) * 2009-10-12 2013-06-25 Keck Graduate Institute Strategy to reduce lactic acid production and control PH in animal cell culture
ES2533074T3 (es) * 2010-04-26 2015-04-07 Novartis Ag Medio de cultivo celular mejorado
RU2614125C2 (ru) * 2010-05-28 2017-03-22 Дженентек, Инк. Снижение уровня лактата и увеличение продукции полипептида путем ингибирования экспрессии лактатдегидрогеназы и киназы пируватдегидрогеназы
TWI637057B (zh) 2012-11-09 2018-10-01 拜爾沙納有限公司 具交替生物反應器用途之不連續進料批次製程
WO2014109858A1 (en) * 2013-01-14 2014-07-17 Amgen Inc. Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
ES2833471T3 (es) 2013-10-11 2021-06-15 Regeneron Pharma Cultivo celular metabólicamente optimizado

Similar Documents

Publication Publication Date Title
JP2016532457A5 (enExample)
Zeltz et al. α11β1 integrin is induced in a subset of cancer-associated fibroblasts in desmoplastic tumor stroma and mediates in vitro cell migration
Jabalee et al. The role of extracellular vesicles in cancer: cargo, function, and therapeutic implications
Coy et al. Viruses of eukaryotic algae: diversity, methods for detection, and future directions
SA520411173B1 (ar) Pd-l1 عوامل ربط ترتبط بـ واستخدامها cd137
Sulaiman et al. CSCs in breast cancer—one size does not fit all: Therapeutic advances in targeting heterogeneous epithelial and mesenchymal CSCs
Padawer et al. Case study: an accelerated 8‐day monoclonal antibody production process based on high seeding densities
HRP20211882T1 (hr) Protutijela protiv cd40 i njihova upotreba
HRP20220081T1 (hr) Bcma i cd3 bispecifična t stanica koja uključuje konstrukte protutijela
JP2018514204A5 (enExample)
RU2018113510A (ru) Химерные рецепторы антигена, нацеленные на psca
IL292650B2 (en) COSTIMULATORY CHIMERIC ANTIGEN RECEPTOR T CELLS TARGETING IL13Ra2
JP2016196468A5 (enExample)
GB2549632A8 (en) Fusion protein comprising three binding domains to 5T4 and CD3
JP2014534207A5 (enExample)
Rolih et al. Development of a vlp-based vaccine displaying an XCT extracellular domain for the treatment of metastatic breast cancer
Gingrich et al. Characterization and potential applications of dog natural killer cells in cancer immunotherapy
EA201101059A1 (ru) Наращивание антитела на основе информации, полученной с помощью антитела
Chalenko et al. Natural isoforms of Listeria monocytogenes virulence factor Inlb differ in c-Met binding efficiency and differently affect uptake and survival Listeria in macrophage
Lee-Theilen et al. Co-expression of CD34, CD90, OV-6 and cell-surface vimentin defines cancer stem cells of hepatoblastoma, which are affected by Hsp90 inhibitor 17-AAG
Ebbinghaus et al. Endogenous signaling molecule activating (ESMA) CARs: A novel CAR design showing a favorable risk to potency ratio for the treatment of triple negative breast cancer
Iikawa et al. Intrinsic oncogenic function of intracellular connexin26 protein in head and neck squamous cell carcinoma cells
Tarasova et al. Principal signalling complexes in haematopoiesis: Structural aspects and mimetic discovery
Shiu et al. The Non-Coding RNA Journal Club: Highlights on Recent Papers—12
Mirani et al. Germination and seedling development of Trapa bispinosa Roxb.